Spherix Global Insights

April 14, 2016

New Study Indicates High Therapy Switching Rates for Multiple Sclerosis Patients in the US & EU, Benefitting Biogen’s Tecfidera, Novartis’ Gilenya & Sanofi’s Aubagio

Download Report Overview

The research, based on analysis of over 2,100 patient records and input from over 400 neurologists, also reveals high anticipation and market opportunity for Roche’s ocrelizumab.

April 14, 2016 – Zug, Switzerland – A recent study conducted by Spherix Global Insights found that the use of oral DMTs significantly increase at the expense of the platform injectables (Biogen’s Avonex and Plegridy, Bayer’s Betaseron/Betaferon, Novartis’ Extavia, Serono’s Rebif, Teva’s Copaxone, and Momenta’s Glatopa) when MS patients are switched away from their first-line therapy.

According to the RealWorld Dynamix™ DMT Switching in Multiple Sclerosis report, nearly 50% of the MS patients receiving DMT treatment have been switched, at least once, to another therapy. Switching is most commonly due to the lack of success of previous agents in reducing the number of relapses, controlling disability accumulation and slowing the progression of the disease.

“With MS diagnosis occurring earlier in the disease course and multiple DMTs now available, patients can move through several switches until finding the agent that best manages their disease,” said Ines Troconis Merolli, Spherix Global Insights’ Neurology Franchise Head, “Our brand analysis found that when deciding which DMT to switch to, a different MOA and the comfort level with the drugs are the top two considerations in the neurologists’ mind.  With switches to oral DMTs, patient request also plays a significant role in brand choice.”

The deep-dive into the DMT switch dynamics in USA and Europe also reveals a positive outlook for Roche’s ocrelizumab. Most neurologists participating in the study confirmed the need for new therapies to treat MS.  There is a fairly high awareness of ocrelizumab already and neurologists identified many of the audited patients as potential candidates for this new agent once approved.

About Spherix Global Insights
Spherix Global Insights is a newly established business intelligence and market research company. We specialize in renal, autoimmune, neurologic and rare disease markets.  Our aim is to apply our commercial experience and unique relationships within core specialty markets to translate data into insight, enabling our clients to make smarter business decisions.

For more information contact: 
Dan Cassidy, Business Development
Telephone:  800-661.0571
Email: info@spherixglobalinsights.com
www.spherixglobalinsights.com